Novartis To Seek Licensing Partner For Pitavastatin
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm is terminating development of its lipid-lowering agent pitavastatin after disappointing Phase II trial results.
You may also be interested in...
Seventh Statin Appoved: Kowa Will Take A Niche Strategy For Livalo
Kowa's decision to emphasize its newly approved statin Livalo'seffect in populations that are hard to treat with other statins is a wise strategy for a late entry to a class dominated by popular generics and well-established brands from marketing powerhouses like Pfizer and AstraZeneca
Seventh Statin Appoved: Kowa Will Take A Niche Strategy For Livalo
Kowa's decision to emphasize its newly approved statin Livalo'seffect in populations that are hard to treat with other statins is a wise strategy for a late entry to a class dominated by popular generics and well-established brands from marketing powerhouses like Pfizer and AstraZeneca
Seventh Statin Appoved: Kowa Will Take A Niche Strategy For Livalo
Kowa's decision to emphasize its newly approved statin Livalo'seffect in populations that are hard to treat with other statins is a wise strategy for a late entry to a class dominated by popular generics and well-established brands from marketing powerhouses like Pfizer and AstraZeneca